07 August 2025
07 August 2025
The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.
With the label expansion, Teva gains an edge over rivals Amgen and Eli Lilly in the CGRP inhibitor arena.
Modeyso is expected to be commercially available in late summer 2025.
Bayer disclosed that its Q2 earnings were inflated by transfer fees at its German football club Bayer Leverkusen.
Astria will receive $16m upfront and is eligible for a further $16m in commercialisation and sales milestones.
H1 sales growth for Novo鈥檚 segment that includes Ozempic and Wegovy was down from the same period in 2024.
Staving off headwinds from Ibrance generic competition, Pfizer鈥檚 Q2 earnings surpassed analyst estimates.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
